ERCC1 and neoplasm: Primary tumours expressing low/no ERCC1 (DLD‐C2) exhibited a significant reduction in fluorescence signal and tumour weight upon oxaliplatin treatment indicating tumour shrinkage (Figs 6C,D and S7).